ARPA-H announced THRIVE, a program that will spend up to $160 million to accelerate custom gene-editing therapies for rare diseases. The effort is structured around seven teams pursuing distinct disease areas, with deadlines for initiating clinical trials by year three for each group. The agency’s goal is to move from early concepts toward bespoke therapies with clinical execution built into the program design. By setting explicit clinical-start timelines, ARPA-H is attempting to reduce the long gap between preclinical promise and patient studies. THRIVE signals sustained federal backing for next-generation editing modalities and could accelerate platform maturation by forcing teams to align experimental design, manufacturing readiness, and clinical operations early in development.